Paul Knox

Dr. Paul Knox

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2011 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
NANabin Amatya
Nabin Amatya
QGQiyong Gong
Qiyong Gong
PKPaul Knox
Paul Knox

31 December 2010 in Vision Research
Verified
Journal Article
Closed access
NBNicola Bruno
Nicola Bruno
PKPaul Knox
Paul Knox
DGDenise D.J. de Grave
Denise D.J. de Grave

13 May 2013 in British Journal of Visual Impairment
Verified
Journal Article
Open access
CTClare Thetford
Clare Thetford
SHSuzanne Hodge
Suzanne Hodge
SHSimon Harding
Simon Harding
STSandra Taylor
Sandra Taylor
PKPaul Knox
Paul Knox
This study reports the results of a qualitative study of patient experiences of receiving treatment for wet age-related macular degeneration with ranibizumab (Lucentis)(R). Treatment involved monthly hospital visits for assessment and, where required, an intravitreal Lucentis injection. Qualitative narrative interviews were conducted with 22 patients, 18 of whom received treatment and were interviewed at two points during their treatment journey. Interviews allowed participants to reflect on their experiences of being assessed for and receiving this treatment. Overall, treated participants reported that while they had been apprehensive about treatment, the actual experience of it was far less unpleasant than they had expected. However, the data also revealed a number of issues surrounding the provision of information about treatment, as well as service delivery issues, which had considerable impact upon their experience.

15 July 2005 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
PKPaul Knox
Paul Knox
JDJillian H. Davidson
Jillian H. Davidson
DADavid Anderson
David Anderson

7 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PKPaul Knox
Paul Knox
FWFelicity D. A. Wolohan
Felicity D. A. Wolohan
A central claim of cultural neuroscience is that the culture to which an individual belongs plays a key role in shaping basic cognitive processes and behaviours, including eye movement behaviour. We previously reported a robust difference in saccade behaviour between Chinese and Caucasian participants; Chinese participants are much more likely to execute low latency express saccades, in circumstances in which these are normally discouraged. To assess the extent to which this is the product of culture we compared a group of 70 Chinese overseas students (whose primary cultural exposure was that of mainland China), a group of 45 participants whose parents were Chinese but who themselves were brought up in the UK (whose primary cultural exposure was western European) and a group of 70 Caucasian participants. Results from the Schwartz Value Survey confirmed that the UK-Chinese group were culturally similar to the Caucasian group. However, their patterns of saccade latency were identical to the mainland Chinese group, and different to the Caucasian group. We conclude that at least for the relatively simple reflexive saccade behaviour we have investigated, culture cannot explain the observed differences in behaviour.

4 May 2020 in Eye
Verified
Journal Article
Open access
PDF file
EWElizabeth Ward
Elizabeth Ward
RWRobin A. Wickens
Robin A. Wickens
AOAbby O’connell
Abby O’connell
LCLucy A. Culliford
Lucy A. Culliford
CRChris A. Rogers
Chris A. Rogers
BRBarnaby C. Reeves
Barnaby C. Reeves
Aims: This study aims to quantify the diagnostic test-accuracy of three visual function self-monitoring tests for detection of active disease in patients with neovascular age-related macular degeneration (nAMD) when compared with usual care. An integrated qualitative study will investigate the acceptability of these home-based testing strategies. Methods: All consenting participants are provided with an equipment pack containing an iPod touch with two vision test applications installed and a paper journal of reading tests. Participants self-monitor their vision at home each week with all three tests for 12–18 months. Usual care continues over this period. Key eligibility criteria are: age ≥50 years; at least one eye with AMD with ≥6–≤42 months since first AMD treatment; and vision not worse than Snellen 6/60, LogMAR 1.04 or 33 letters. The primary outcome, and reference standard, is diagnosis of active disease during usual care monitoring in the Hospital Eye Service. Secondary outcomes include duration of study participation, ability of participants to do the tests, adherence to weekly testing and acceptability of the tests to participants. Conclusions: Recruitment is in progress at five NHS centres. Challenges in procuring equipment, setting up the devices and transporting devices containing lithium batteries to participating sites delayed the start of recruitment. The study will describe the performance of the tests self-administered at home in detecting active disease compared to usual care monitoring. It will also describe the feasibility of the NHS implementing patient-administered electronic tests or similar applications at home for monitoring health.